Home About Us Media Kit Subscriptions Links Forum
APPEARED IN


View All Articles

Download PDF

FAMOUS INTERVIEWS

Directories:

SCHOLARSHIPS & GRANTS

HELP WANTED

Tutors

Workshops

Events

Sections:

Books

Camps & Sports

Careers

Children’s Corner

Collected Features

Colleges

Cover Stories

Distance Learning

Editorials

Famous Interviews

Homeschooling

Medical Update

Metro Beat

Movies & Theater

Museums

Music, Art & Dance

Special Education

Spotlight On Schools

Teachers of the Month

Technology

Archives:

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

1995-2000


APRIL 2004

A Better Way to Treat Children With Cancer

Children undergoing a stem cell transplant to treat leukemia, blood disorders or other types of cancer can safely undergo a less toxic treatment regimen than one that is traditionally used, report researchers from Columbia University Medical Center and NewYork-Presbyterian Hospital in the journal Bone Marrow Transplantation.

Typically, such patients have their immune system destroyed with high doses of chemotherapy or radiation before the transplant procedure. This allows the transplanted stem cells to "take" and start producing a new, healthy immune system.

However, the destruction of the immune system leaves youngsters vulnerable to potentially life-threatening infections and dangerously low white and red-blood cell counts before the new immune system begins functioning—a process that can take weeks or months. And in the long run, the high-dose chemotherapy or radiation may damage fertility, stunt growth and increase the risk of a second, unrelated cancer later in life.

"Physicians would like to find a way to avoid the toxicity of this treatment, known as myeloablation," said Dr. Mitchell S. Cairo, professor of pediatrics, medicine and pathology at Columbia University College of Physicians and Surgeons and chief of the Division of Pediatric Hematology and Blood and Marrow Transplantation at the Children's Hospital of New York-Presbyterian. "Some of these children may die of infections in the first few weeks after transplant, and if they do survive and the transplant is a success, they can have problems further down the road."

"Leaving the immune system somewhat intact may help prevent infections, particularly in those children who have relatively few stem cells available for transplant," said Dr. Cairo.

In the new study, Dr. Cairo and colleagues tried a variety of less toxic treatment regimens on a group of 21 children, teens and young adults, all under the age of 21. The patients had cancers or blood disorders of the immune system.

"We used what we call "reduced intensity" regimens that used chemotherapy drugs, and in one case radiation, to weaken the patient's own immune system," said Dr. Cairo. "This has been tried in adults with some success, but there is little data on this in children."

The children were then given transplants of stem cells collected from the umbilical cord blood of unrelated donors or stem cells from the bone marrow or blood of relatives. The children were also treated with medication to prevent graft-versus-host disease (GVHD), a potentially dangerous condition that occurs when the transplanted cells attack the patient's tissue. GVHD can cause a blistering rash, enlarged liver and intestinal problems such as diarrhea.

The researchers found that 85 percent or more of the children in the study achieved at least a 50 percent donor chimerism, meaning their immune system contained a mixture of the patient's and the donor's cells. This is a sign that the graft is "taking." In about 24 percent of cases, the graft failed to take. "These numbers are similar to those seen in adults undergoing a reduced intensity regimen," said Dr. Cairo. "However, the results should be interpreted with caution."

The study included children with a wide variety of ailments, from leukemia and Hodgkin's disease to an inherited blood disorder called beta-thalassemia. The study participants had a variety of regimens using different combinations of drugs. "Larger studies are needed to look at how these results will vary depending on a child's diagnosis and drug treatment," said Dr. Cairo. "And a long-term follow-up is needed to determine their risk of GVHD and side effects of treatment, such as growth stunting, secondary cancers and infertility."#

COMMENT ON THIS ARTICLE

Name:

Email:
Show email
City:
State:

 


 

 

 

Education Update, Inc.
All material is copyrighted and may not be printed without express consent of the publisher. © 2005.